LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Medtronic PLC

Gesloten

SectorGezondheidszorg

94.03 1.24

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

92.93

Max

94.27

Belangrijke statistieken

By Trading Economics

Inkomsten

-17M

1B

Verkoop

-349M

8.6B

K/W

Sectorgemiddelde

25.638

35.733

EPS

1.26

Dividendrendement

3.06

Winstmarge

12.124

Werknemers

95,000

EBITDA

-50M

2.2B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+7.42% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.06%

3.13%

Volgende Winsten

18 nov 2025

Volgende dividenddatum

17 okt 2025

Volgende Ex Dividend datum

26 sep 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

133M

119B

Vorige openingsprijs

92.79

Vorige sluitingsprijs

94.03

Nieuwssentiment

By Acuity

26%

74%

82 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Medtronic PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 aug 2025, 11:39 UTC

Winsten

Medtronic Posts Higher 1Q Revenue, Boosts Outlook as Tariffs Ease

21 mei 2025, 11:38 UTC

Winsten
Acquisities, Fusies, Overnames

Medtronic Boosts Dividend, Plans to Separate Diabetes Business and Targets Revenue Growth for Year

19 aug 2025, 20:33 UTC

Winsten
Acquisities, Fusies, Overnames

These Stocks Moved the Most Today: Intel, Home Depot, Palo Alto, Viking Therapeutics, Palantir, Medtronic, and More -- Barrons.com

19 aug 2025, 17:41 UTC

Winsten
Acquisities, Fusies, Overnames

Medtronic Posts Earnings Beat and Elliott Buys Stake. The Stock Falls Anyway. -- Barrons.com

19 aug 2025, 13:35 UTC

Populaire aandelen

Stocks to Watch Tuesday: Intel, Medtronic, Home Depot -- WSJ

19 aug 2025, 12:48 UTC

Winsten
Acquisities, Fusies, Overnames

Medtronic Posts Earnings Beat and Elliott Buys Stake. The Stock Falls Anyway. -- Barrons.com

19 aug 2025, 11:27 UTC

Winsten

Medtronic Posts Earnings Beat and Elliott Buys Stake. The Stock Falls Anyway. -- Barrons.com

19 aug 2025, 10:51 UTC

Winsten

Medtronic Sees FY26 Reported Revenue Growth 6.5%-6.8% >MDT

19 aug 2025, 10:50 UTC

Winsten

Medtronic Had Seen FY26 Adjusted EPS $5.50-$5.60 >MDT

19 aug 2025, 10:50 UTC

Winsten

Medtronic Raises FY26 View To Adj EPS $5.60-Adj EPS $5.66 >MDT

19 aug 2025, 10:50 UTC

Winsten

Medtronic Cuts FY26 Potential Tariff Impact View to About $185M From $200M-$350M >MDT

19 aug 2025, 10:49 UTC

Winsten

Medtronic Raises FY26 Adjusted EPS Growth View to About 4.5% From About 4%, Excluding Potential Tariff Impact >MDT

19 aug 2025, 10:48 UTC

Winsten

Medtronic Still Sees FY26 Organic Revenue Up About 5% >MDT

19 aug 2025, 10:45 UTC

Winsten

Medtronic 1Q Medical Surgical Portfolio Rev $2.08B >MDT

19 aug 2025, 10:45 UTC

Winsten

Medtronic 1Q Cardiovascular Portfolio Rev $3.29B >MDT

19 aug 2025, 10:45 UTC

Winsten

Medtronic 1Q Neuroscience Portfolio Rev $2.42B >MDT

19 aug 2025, 10:45 UTC

Winsten

Medtronic 1Q Organic Revenue Up 4.8% >MDT

19 aug 2025, 10:45 UTC

Winsten

Medtronic 1Q EPS 81c >MDT

19 aug 2025, 10:45 UTC

Winsten

Medtronic 1Q Net $1.04B >MDT

19 aug 2025, 10:45 UTC

Winsten

Medtronic 1Q Diabetes Rev $721M >MDT

19 aug 2025, 10:45 UTC

Winsten

Medtronic 1Q Sales $8.58B >MDT

19 aug 2025, 10:45 UTC

Winsten

Medtronic 1Q Adj EPS $1.26 >MDT

19 aug 2025, 09:12 UTC

Populaire aandelen

Stocks to Watch Tuesday: Intel, Palo Alto, Tegna, Home Depot -- WSJ

12 jun 2025, 13:01 UTC

Acquisities, Fusies, Overnames

Medtronic Targeting Completion of Planned Separation Within 18 Mos of Initial Announcement >MDT

21 mei 2025, 17:23 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Medtronic to Separate Diabetes Business as Stand-Alone Company -- 2nd Update

21 mei 2025, 11:39 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Medtronic to Separate Diabetes Business as Stand-Alone Company -- Update

21 mei 2025, 10:52 UTC

Winsten

Medtronic Sees FY26 Adjusted EPS Up About 4% Excluding Potential Impacts From Increased Tariffs >MDT

21 mei 2025, 10:51 UTC

Winsten

Medtronic Sees FY26 Adj EPS $5.50-Adj EPS $5.60, Including Potential Tariff Impact >MDT

21 mei 2025, 10:50 UTC

Winsten

Medtronic Sees FY26 Reported Revenue Up 4.8%-5.1% if Recent Forex Rates Hold >MDT

21 mei 2025, 10:49 UTC

Winsten

Medtronic Sees FY26 Organic Revenue Growth Up About 5% >MDT

Peer Vergelijking

Prijswijziging

Medtronic PLC Prognose

Koersdoel

By TipRanks

7.42% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 99.89 USD  7.42%

Hoogste 115 USD

Laagste 78 USD

Gebaseerd op 26 Wall Street-analisten die 12-maands prijsdoelen bieden voor Medtronic PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

26 ratings

13

Buy

12

Hold

1

Sell

Technische score

By Trading Central

83.26 / 84.875Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

82 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.
help-icon Live chat